pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

867 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT801Endpoints604BioPharma Dive231onclive165Fierce Biotech74BioSpace71raps32globenewswire health20fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • EU reaches provisional deal on Critical Medicines Act
    The Critical Medicines Act reached its next milestone on Tuesday, after the European Parliament and the Council provisionally voted it through. The proposed regulation aims to improve the European…
    Endpoints · 2mo ago↗ source
  • FDA Commissioner Makary resigns
    FDA Commissioner Marty Makary has resigned after his job status hung in the balance for days. President Donald Trump confirmed the news Tuesday in a social media post. Makary’s decision centered ...
    Endpoints · 2mo ago↗ source
  • Iran war disruptions begin to emerge upstream of the pharma supply chain
    As the Iran war enters its third month, its knock-on effects on raw materials, energy costs and shipping are beginning to be felt in the pharma industry. While the Middle East is barely a player ...
← prev
page 27 of 35
next →
20
fda medwatch20
fda recalls16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 2mo ago
↗ source
  • What I learned at a journalism fellowship about covering healthcare AI
    Last week, I was reminded that reporting on AI in healthcare requires continuous scrutiny of the incentives that drive it. Thanks to a fellowship hosted by SABEW, in partnership with ...
    Endpoints · 2mo ago↗ source
  • Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
    A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.
    BioPharma Dive · 2mo ago↗ source
  • Five burning Qs for Isomorphic Labs after $2.1B raise for AI biotech
    Isomorphic Labs said Tuesday it had closed a $2.1 billion Series B round, cementing its bellwether role in using AI for drug discovery. For privately held companies, Isomorphic’s raise is the secon…
    Endpoints · 2mo ago↗ source
  • Pfizer and Arvinas give disappointing breast cancer drug to Rigel
    Pfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals. T…
    Endpoints · 2mo ago↗ source
  • Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
    Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful, but also aggressive,” Anderson said on a first-qu…
    Endpoints · 2mo ago↗ source
  • Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal
    Plus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…
    Endpoints · 2mo ago↗ source
  • Knit Health raises $11.6M for 'fundamentally different' approach to healthcare AI
    A startup that spun out of UC Berkeley aims to improve healthcare operations by getting AI to think like a doctor would. Knit Health launched with $11.6 million in seed funding co-led by Uncork Cap…
    Endpoints · 2mo ago↗ source
  • Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
    The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.
    BioPharma Dive · 2mo ago↗ source
  • A year after Vertex’s big launch, pain drug research faces a pivotal moment
    Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
    BioPharma Dive · 2mo ago↗ source
  • Flagship startup Serif says it has solved non-viral gene therapy in monkeys
    BOSTON — Serif Biomedicines, a startup launched last month by Flagship Pioneering, believes it has solved two technical challenges that have long prevented gene therapy from being delivered without…
    Endpoints · 2mo ago↗ source
  • Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
    It's becoming Hengrui Pharma's world, and some Western drugmakers are just living in it. China's largest pharma company, which boasts one of the biggest pipelines in the industry, has lined up Bris…
    Endpoints · 2mo ago↗ source
  • Optum Rx unveils pharmacy model with clear fees, building on transparency push
    UnitedHealth Group’s Optum Rx on Monday unveiled a new approach to prescription drug benefits that it said offers its customers transparency into the entire drug supply chain. Under the new model,…
    Endpoints · 2mo ago↗ source
  • Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
    It seems there’s room for two in the MASH market. When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat the fatty liver disease, some investors thought it wou…
    Endpoints · 2mo ago↗ source
  • GSK cuts deal with Sino to broaden reach of hepatitis B drug
    The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.
    BioPharma Dive · 2mo ago↗ source
  • Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push
    Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues. The drugmaker published a new five-year business plan on Monday ...
    Endpoints · 2mo ago↗ source
  • New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in China
    Plus, label expansions for two drugs targeting rare diseases, and Genmab scraps a Phase 1 cancer trial: 🧠 Novo's Parkinson's cell therapy finds a biotech home: Novo Nordisk has found a home for an…
    Endpoints · 2mo ago↗ source
  • Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone
    San Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more t…
    Endpoints · 2mo ago↗ source
  • Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
    Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.
    BioPharma Dive · 2mo ago↗ source
  • Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win
    Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics rec…
    Endpoints · 2mo ago↗ source
  • Biotech layoffs are easing, but is the worst over?
    BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.
    BioPharma Dive · 2mo ago↗ source
  • European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapy
    Drug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just outside of Boston is poised to becom…
    Endpoints · 2mo ago↗ source
  • CSL sinks to nine-year low on revenue warning, $5B write-down
    CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by about 4% and said it would have to take a new $5 billion impairment charge. The ...
    Endpoints · 2mo ago↗ source